Status:
UNKNOWN
Effects of the Direct Interaction Between Streptococcus Salivarius 24SMBc and Streptococcus Oralis 89a and the Respiratory Epithelium in Children
Lead Sponsor:
Federico II University
Conditions:
Allergy
Eligibility:
All Genders
6-12 years
Phase:
PHASE3
Brief Summary
Allergic rhinoconjunctivitis is a pathology of the nasal and conjunctival mucosa induced by Immunoglobulin E (IgE) mediated inflammation following allergic exposure. This condition represents a global...
Eligibility Criteria
Inclusion
- children aged 6-12 months with allergic rhinoconjunctivitis
Exclusion
- concomitant presence of chronic pathologies,
- malformations of the respiratory tract and facial cranium,
- tumors,
- neurological diseases,
- metabolic pathologies,
- cystic fibrosis,
- immunodeficiencies,
- history of epistaxis,
- alteration of coagulation factors,
- history of apnea,
- ciliary dyskinesia,
- treatment with topical drugs nasal steroids and / or oral anti-histaminics or antibiotic treatment in the 3 months prior to enrollment.
Key Trial Info
Start Date :
March 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2018
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03449836
Start Date
March 1 2018
End Date
December 31 2018
Last Update
March 1 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.